Trial Profile
Aromatase Inhibitors in Premenopausal Breast Cancer Patients With Chemotherapy-Induced Ovarian Failure.
Status:
Discontinued
Phase of Trial:
Phase II
Latest Information Update: 10 Nov 2021
Price :
$35
*
At a glance
- Drugs Anastrozole (Primary)
- Indications Breast cancer
- Focus Pharmacodynamics
- 30 Jan 2012 Planned number of patients changed from 50 to 150 as reported by ClinicalTrials.gov.
- 20 Jan 2011 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.
- 28 Oct 2009 Planned end date changed from 1 Jan 2015 to 1 Jan 2016 as reported by ClinicalTrials.gov.